tradingkey.logo

CHMP Recommends Granting Conditional Marketing Authorisation For Kayshild

ReutersJan 30, 2026 12:31 PM

- EMA's CHMP:

  • STARTED A REVIEW OF TAVNEOS FOLLOWING EMERGING INFORMATION THAT RAISES QUESTIONS REGARDING THE DATA INTEGRITY OF THE ADVOCATE STUDY

  • RECOMMENDED GRANTING A CONDITIONAL MARKETING AUTHORISATION FOR KAYSHILD (SEMAGLUTIDE)

  • RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR IMFINZI

  • RECOMMENDS GRANTING MARKETING AUTHORISATION FOR SUPEMTEK

  • RECOMMENDS GRANTING CONDITIONAL MARKETING AUTHORISATION FOR REZUROCK FOLLOWING RE-EXAMINATION

  • FINALISED ASSESSMENT OF APPLICATION TO EXTEND USE OF MOUNJARO

  • EXTEND USE OF MOUNJARO TO INCLUDE TREATMENT OF SYMPTOMATIC LONG-TERM HEART FAILURE WITH PRESERVED EJECTION FRACTION IN OBESE ADULTS

  • DID NOT RECOMMEND SEPARATE INDICATION SHOULD BE GRANTED FOR TREATMENT OF HFPEF, AGREED TO INCLUDE RELEVANT DATA FROM STUDY

Further company coverage: [NOVOb.CO]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI